S. Vasu

K. Coombes, C. Hofmeister, R. Garzon, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study

J. Byrd, R. Garzon, G. Behbehani, 2020, Leukemia & lymphoma.

Decitabine priming enhances the anti-leukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia Running head: Decitabine and XPO1 inhibition in AML

Ramasamy, Xueyan, R. Garzon, 2015 .

Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic.

H. Rugo, G. Lyman, P. Westervelt, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome

M. Grever, J. Byrd, R. Garzon, 2020, American journal of hematology.

Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia

J. Byrd, R. Garzon, G. Behbehani, 2020, International journal of hematologic oncology.

Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy

C. Hofmeister, A. Satoskar, L. Andritsos, 2016, Bone Marrow Transplantation.

The Incidence of Invasive Fungal Infections in Patients With AML Treated With a Hypomethylating Agent.

G. Behbehani, J. Blachly, B. Bhatnagar, 2020, Clinical lymphoma, myeloma & leukemia.

A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485

M. Caligiuri, C. Bloomfield, M. Grever, 2017, Haematologica.

Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.

J. Byrd, X. Mo, N. Muthusamy, 2020, Cytotherapy.

Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy

D. Sampath, X. Mo, K. Rogers, 2022, Blood advances.

A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation.

M. Berg, R. Childs, J. Davidson-Moncada, 2015, Cytotherapy.

Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant

C. Hofmeister, A. Ruppert, L. Andritsos, 2015, Leukemia & lymphoma.

Feasibility of Centralized Electronic Patient-Reported Outcome (ePRO) Collection By an Outcome Registry, a CIBMTR Study of Patients on the Centers for Medicaid & Medicare Coverage with Evidence Development (CMS CED) Myelodysplasia Protocol

M. Horowitz, J. Pidala, Stephanie J. Lee, 2020 .

None of the above: thrombotic microangiopathy beyond TTP and HUS.

S. Cataland, S. Vasu, C. Masias, 2017, Blood.

Molecular Complete Remission Following Ivosidenib in a Patient With an Acute Undifferentiated Leukemia.

J. Byrd, A. Walker, S. Vasu, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Comparison of Two Doses of Antithymocyte Globulin in Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (allo HSCT).

A. Ruppert, D. Benson, Y. Efebera, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia

J. Byrd, X. Mo, D. Benson, 2018, International immunology.

Interferon-γ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells*

J. Byrd, J. Blachly, X. Mo, 2016, The Journal of Biological Chemistry.

Adoptive Transfer of Escalating Doses of Ex Vivo Expanded Autologous Natural Killer (NK) Cells In Patients with Advanced Malignancies Following Bortezomib Treatment to Sensitize to NK-TRAIL Cytotoxicity

K. Keyvanfar, D. Stroncek, M. Berg, 2010 .

MicroRNAs activate natural killer cells through Toll-like receptor signaling.

M. Caligiuri, K. Ghoshal, C. Hofmeister, 2013, Blood.

Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.

R. Garzon, G. Marcucci, M. Phelps, 2015, Blood.

Tagraxofusp in Blastic Plasmacytoid Dendritic‐Cell Neoplasm

M. Konopleva, H. Kantarjian, A. Lane, 2019, The New England journal of medicine.

Activation of the Intracellular Pattern Recognition Receptor NOD2 Promotes Acute Myeloid Leukemia (AML) Cell Apoptosis and Provides a Survival Advantage in an Animal Model of AML

J. Byrd, Jonathan P Butchar, R. Santhanam, 2020, The Journal of Immunology.

Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuria.

N. Geller, N. Young, P. Scheinberg, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.

H. Rugo, G. Lyman, P. Westervelt, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

A systematic review of diagnostic, prognostic, and risk blood and urine biomarkers of transplant-associated thrombotic microangiopathy

S. Vasu, M. Schoettler, Harshil Bhatt, 2023, Frontiers in Immunology.

Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults

S. Davies, S. Jaglowski, Qiuhong Zhao, 2021, Blood advances.

Transfusion support for stem cell transplant recipients.

B. Adkins, Garrett S. Booth, S. Vasu, 2020, Seminars in hematology.

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

J. Armitage, H. Rugo, G. Lyman, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis BMT CTN 1101Open for Accrual June 2012Open for Accrual June 2012.

B. Logan, J. Magenau, C. Cutler, 2022, Transplantation and cellular therapy.

Cellular therapies: Hematology and beyond.

S. Vasu, 2023, Seminars in hematology.

Tocilizumab for steroid refractory acute graft-versus-host disease

C. Hofmeister, L. Andritsos, D. Benson, 2016, Leukemia & lymphoma.

An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor

L. Andritsos, S. Devine, S. Jaglowski, 2014, Bone Marrow Transplantation.

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older AML patients.

Shannon R. McCurdy, J. Ritz, M. Carroll, 2022, Blood.

Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS

S. Jaglowski, Qiuhong Zhao, A. Mims, 2020, Leukemia & lymphoma.

A phase II multi-center study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplantation for high-risk myelodysplasia (and older patients with acute myeloid leukemia: CALGB 100801 (Alliance).

K. Owzar, R. Vij, V. Hárs, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome

E. Leifer, P. Westervelt, F. Appelbaum, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML

J. Byrd, R. Garzon, G. Behbehani, 2019, Investigational New Drugs.

BMT CTN 1803: Trial to Investigate If Haploidentical Natural Killer Cells (CSTD002) Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

S. Devine, E. Krakow, B. Logan, 2020 .

Treatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN)

A. Lane, D. Rizzieri, Justin Taylor, 2022, Leukemia & lymphoma.

Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.

M. Caligiuri, G. Lozanski, K. Heider, 2016, Blood.

The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60years.

S. Devine, S. Vasu, S. Wall, 2017, Blood reviews.

Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience

D. Benson, Y. Efebera, S. Jaglowski, 2021, Cancers.

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.

C. Bloomfield, J. Byrd, K. Metzeler, 2018, Blood advances.

Bringing Patient and Caregivers Voices to the Clinical Trial Chorus: A Report from the BMT CTN Patient and Caregiver Advocacy Task Force.

A. Shimamura, N. Mortier, B. Nuechterlein, 2022, Transplantation and cellular therapy.

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need.

M. Konopleva, H. Kantarjian, A. Lane, 2022, Blood.

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis of a Pivotal Trial

A. Lane, C. Brooks, N. Pemmaraju, 2022, Blood.

Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

M. Konopleva, A. Lane, C. Brooks, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AML-465 Tagraxofusp, an Anti-CD123 Therapy, in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm: Sub-Analysis of a Pivotal Trial by Age and Baseline Disease Involvement.

M. Konopleva, H. Kantarjian, A. Lane, 2021, Clinical Lymphoma, Myeloma & Leukemia.

Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.

C. Hofmeister, G. Lozanski, L. Andritsos, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies

N. Geller, M. Perales, H. Heslop, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of Salvage Regimens Post CAR-T Cell Therapy for Patients with Diffuse Large B-Cell Lymphoma.

A. Kittai, S. Jaglowski, M. de Lima, 2022, Transplantation and cellular therapy.

A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML)

Scott E. Smith, B. Wood, M. Maris, 2016 .

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Scott E. Smith, B. Wood, M. Maris, 2016 .

FLT3L and plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcome.

C. Hofmeister, Zhijin Fan, S. Devine, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Calcineurin Inhibitor-Free Graft-Versus-Host Disease (GVHD) Prophylaxis in Hematopoietic Cell Transplantation (HCT) with Myeloablative Conditioning Regimens (MAC) and HLA-Matched Donors: Results of the BMT CTN 1301 Progress II Trial

N. Geller, M. Perales, H. Heslop, 2021 .

Cardiovascular Toxicity and Clinical Outcomes Following Chimeric Antigen Receptor T-Cell Infusion (CART) for Lymphoid Malignancies

P. Binkley, A. Vallakati, S. Jaglowski, 2020 .

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors

J. Byrd, G. Lozanski, C. Brooks, 2018, Haematologica.

Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation

D. Benson, Y. Efebera, S. Jaglowski, 2019, Cancers.

Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.

M. Pasquini, J. Wingard, K. Ballen, 2019, Blood advances.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

M. Arcasoy, S. Verstovsek, D. Mclornan, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?

C. Hofmeister, L. Andritsos, D. Benson, 2018, Bone Marrow Transplantation.

Outcomes of Bone Marrow Compared to Peripheral Blood for Haploidentical Transplantation

D. Benson, Y. Efebera, S. Jaglowski, 2021, Journal of clinical medicine.

Discharge Disposition Following Hematopoietic Cell Transplantation: Predicting the Need for Rehabilitation and Association with Survival.

Qiuhong Zhao, A. Rosko, S. Vasu, 2021, Transplantation and cellular therapy.

Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients

C. Hofmeister, L. Andritsos, D. Benson, 2018, Bone Marrow Transplantation.

Have We Achieved a Goldilocks Grade of Graft-Versus-Host Disease?

S. Jaglowski, S. Vasu, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Emerging immunotherapies in older adults with acute myeloid leukemia.

W. Blum, S. Vasu, 2013, Current opinion in hematology.

T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes

M. Pasquini, J. Wingard, K. Ballen, 2018, Blood.

Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant

D. Benson, Y. Efebera, S. Jaglowski, 2022, Frontiers in Oncology.

Outcomes of the cyclophosphamide, vincristine, prednisone (CVP) +/- rituximab (R-CVP) regimen in older patients with newly diagnosed Ph- acute lymphoblastic leukemia.

J. Byrd, G. Behbehani, J. Blachly, 2020, Leukemia research.

Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

M. Konopleva, H. Kantarjian, A. Lane, 2018, Blood.

Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

M. Konopleva, H. Kantarjian, A. Lane, 2016 .

Cutaneous graft-versus-host disease within chronic photodamaged skin: A case series demonstrating role for topical 5-fluorouracil

B. Kaffenberger, S. Jaglowski, A. Mims, 2023, JAAD case reports.

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission.

Shannon R. McCurdy, M. Carroll, M. Perales, 2019, Blood.

Type of prior genotoxic insult determines the genomic characteristics of therapy‐related myeloid neoplasms

J. Byrd, G. Behbehani, J. Blachly, 2021, American journal of hematology.

CAR T-Cell Therapy: Clinical Outcomes, Patient Selection and Financial Metrics with Tisagenlecleucel and Axicabtagene Ciloleucel, a Single Center Experience

S. Jaglowski, Z. Braunstein, J. Brammer, 2020 .

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for 30-Day Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma

C. Hofmeister, A. Ruppert, L. Andritsos, 2014, Bone Marrow Transplantation.

Incidence, characteristics, and risk factors of venous thromboembolism in adolescent and young adult acute lymphoblastic leukemia patients receiving peg-asparaginase.

G. Behbehani, J. Blachly, Qiuhong Zhao, 2019, Journal of Clinical Oncology.

Epitope spread in chronic mucosal GVHD: mucous membrane pemphigoid resolution with rituximab

B. Kaffenberger, S. Vasu, Sara B Huff, 2019, International journal of dermatology.

Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia.

J. Byrd, R. Garzon, G. Behbehani, 2018 .

Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population.

J. Tisdale, H. Malech, R. Wesley, 2008, Blood.

A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models

R. Baiocchi, L. Alinari, N. Muthusamy, 2023, Experimental Hematology & Oncology.

BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin’s lymphomas

C. Hofmeister, L. Andritsos, D. Benson, 2019, Bone Marrow Transplantation.

Preliminary analysis of a phase 1/2 study of NEXI-001 donor-derived multi-antigen-specific CD8+ T-cells for the treatment of relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic cell transplantation (HCT).

M. Perales, V. Edavana, R. Knight, 2021 .

A Pilot Phase I Trial of IL-21 Expanded Ideal-Donor Natural Killer (NK) Cells in Combination with Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas (CTCL) or Adult T-Cell Leukemia/Lymphomas (ATLL)

Amanda R. Campbell, S. Devine, M. de Lima, 2021, Blood.

Maintenance Ruxolitinib Is Associated with Low Rates of Chronic Gvhd Requiring Systemic Treatment in Older Adults with AML/MDS Undergoing Allogeneic HCT: Results of a Phase II Multicenter Trial

A. El-Jawahri, Z. DeFilipp, Yi-Bin Chen, 2023, Blood.

Prolonged Post-Transplant Ruxolitinib Therapy is Associated with Protection from Severe Gvhd after Allogeneic HCT

Yi-Bin Chen, A. El-Jawahri, Z. DeFilipp, 2022, Transplantation and Cellular Therapy.